Key result
This review summarizes the clinical settings requiring laboratory measurement of target-specific oral anticoagulants and the available data on their interactions with other laboratory tests.
This review outlines the specific clinical settings where laboratory measurement of target-specific oral anticoagulants is needed and discusses their potential to interfere with other laboratory tests.
May guide clinicians on when to measure target-specific oral anticoagulants and recognize test interferences; leaves open need for prospective validation.
Target-specific oral anticoagulants are approved for use for the prevention of stroke in atrial fibrillation and for the prevention and treatment of venous thrombosis without the need for laboratory monitoring. However, there are clinical settings in which laboratory measurement of anticoagulant effect is needed. These may include patients with life-threatening bleeding or those requiring emergency surgery, in the setting of renal or hepatic failure, or patients with thrombosis on therapy. This chapter reviews the use of laboratory testing to assess the anticoagulant effect of these drugs. In addition, because these drugs can interfere with other laboratory testing, available data on these interactions are presented.
No takes yet. Share an insight, caveat, or question.
Barbara A. Konkle (2014) conducted a review in Atrial fibrillation and venous thrombosis. Laboratory testing for target-specific oral anticoagulants was evaluated. This review summarizes the clinical settings requiring laboratory measurement of target-specific oral anticoagulants and the available data on their interactions with other laboratory tests.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: